Despite the irreplaceable effects of EPO or DA on anemia management in patients with CKD,1–3,7–9 recent large-scale randomized controlled trials15–18 strongly suggested harmful effects of higher doses of EPO or DA per se as well as higher Hb levels close to normal (>13 g/dL). This evidence concerns the gene GSTM1 and anemia.